Equity Overview
Price & Market Data
Price: $0.085
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $410,932,512
Volume: 0
Performance Metrics
1 Week: 3.66%
1 Month: 63.46%
3 Months: 63.46%
6 Months: 41.67%
1 Year: 325.0%
YTD: -15.00%
Company Details
Employees: 612
Sector: Health technology
Industry: Pharmaceuticals: other
Country: United Kingdom
Details
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. The company operates in Germany, Austria, Netherlands, Switzerland, Italy, Spain, and internationally, as well as the United Kingdom. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.